Targeting glucocorticoid receptor to enhance immunotherapy response in triple negative breast cancer
Abstract Background Immune checkpoint blockade (ICB) therapies for triple negative breast cancer (TNBC) have yielded limited clinical benefits, which may be attributed to the immunosuppressive tumor immune microenvironment (TIME). Glucocorticoid receptor (GR) has long been thought to suppress immuni...
I tiakina i:
| Ngā kaituhi matua: | , , , , , , , , |
|---|---|
| Hōputu: | Artigo |
| Reo: | Inglês |
| I whakaputaina: |
BMC
2026-01-01
|
| Rangatū: | Breast Cancer Research |
| Ngā marau: | |
| Urunga tuihono: | https://doi.org/10.1186/s13058-026-02230-x |
| Ngā Tūtohu: |
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!
|